The latest development of intelligent antithrombotic patches by American scientists
December 09, 2016 Source: WuXi PharmaTech
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Recently, a team from Professors of the University of North Carolina at Chapel Hill and North Carolina State University, Professor Gu Yong, and Professor Caterina Gallippi developed a team. A "smart anti-thrombosis" patch provides a new strategy for the prevention and treatment of thrombosis. This achievement has also recently been published online in the leading academic journal "Advanced Materials" in the field of materials science.
Thrombosis is the world's top three lethal vascular diseases caused by clots produced in the body, and 1-3 out of every 1,000 people are sick. When the clot is formed, it will block the normal blood circulation of the human body, leading to a series of serious consequences such as pulmonary embolism, heart disease or stroke. According to statistics, China is the country with the most cases of thrombosis; in the United States, between 100,000 and 300,000 people die of venous thrombosis each year, and the number of hospitalizations exceeds 500,000.
Currently, conventional treatments rely on blood thinners such as heparin and warfarin. Although these drugs are effective, they are quite cumbersome in the actual use process - in order to ensure that the amount of heparin is in the proper range, patients need to regularly detect coagulation. If the concentration of heparin in the body is too high, the patient will have a risk of spontaneous bleeding; and if the concentration of heparin is too low, it may not be able to prevent the recurrence of thrombosis.
“We wanted to develop a patch that automatically monitors the patient's blood. It automatically releases the drug when the patient needs it,†said Professor Gu Yu, one of the co-authors of this paper. “This will be a physiological signal. Responsive, thus achieving a system of self-regulation." In recent years, Professor Gu Yu's research group has innovatively proposed the design of transdermal microneedle patches that can respond biologically, and realizes intelligent subcutaneous delivery of dose-controllable drugs. Related inventions include a smart insulin patch that responds to blood glucose, an islet cell patch, and a patch that responds to a tumor microenvironment in response to a sustained release immunological checkpoint (PD-1/CTLA4) antibody.
Single Use Trocar Site Closure Device
A fascial closure device is a laparoscopic instrument used to close the fascia, the layer of tissue that covers and separates abdominal organs and muscles. The device is used during laparoscopic surgery to create a secure closure of the fascia after the surgical procedure is complete.
The fascial closure device consists of a needle and suture material attached to a handle. A needle is used to puncture the fascia, then suture material is passed through the puncture site and tied tightly to close the fascia. The device's handle is used to control the movement of the needle and suture material, allowing precise placement and closure of the fascia.
The use of fascial closure devices during laparoscopic surgery can help reduce the risk of postoperative complications such as hernias, wound infections, and intestinal obstruction. It also closes the fascia more quickly and efficiently, reducing the overall time required for the procedure.
Single Use Trocar Site Closure Device,Medical Use Fascial Closure System,Single Use Fascial Closure System,Exit Fascia Closure Device
Changzhou Weipu Medical Devices Co., Ltd. , https://www.cnweipumedical.com